Sinovac plans to use the net proceeds of the offering to fund the acquisition and expansion of production facilities, the enhancement of production lines, the research and development of product candidates, the expansion of product pipeline, and general corporate purposes (including an undetermined amount for potential acquisitions).
UBS Securities LLC and
This offering will be made under Sinovac's currently effective shelf
registration statement on Form F-3 filed with the Securities and Exchange
Commission on
Copies of the preliminary prospectus supplement and the accompanying
prospectus may be obtained from UBS Securities LLC, Attention: Prospectus
Department, 299 Park Avenue,
About Sinovac
Sinovac Biotech Ltd. is a
Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations, assumptions, estimates and projections about the company and the industry in which the company operates. The company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or to changes in its expectations, except as may be required by law.
For further information, please contact: Helen G. Yang Sinovac Biotech Ltd. Tel: +86-10-8289-0088 x9871 Fax: +86-10-6296-6910 Email: info@sinovac.com Investors: Amy Glynn/Stephanie Carrington The Ruth Group Tel: +1-646-536-7023/7017 Email: aglynn@theruthgroup.com scarrington@theruthgroup.com Media: Janine McCargo The Ruth Group Tel: +1-646-536-7033 Email: jmccargo@theruthgroup.com
SOURCE Sinovac Biotech Ltd.